{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen J"],"funding":["National Natural Science Foundation of China","Jinling Hospital","Key R and D Program in Jiangsu Province"],"pagination":["17588359231225036"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10901068"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16"],"pubmed_abstract":["<h4>Background</h4>Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, only about 20% of NSCLC patients can benefit from this treatment. At present, whether patients with driving gene-positive NSCLC can benefit from immunotherapy is one of the hot issues. Therefore, we conducted a meta-analysis to evaluate the efficacy of immunotherapy in patients with oncogene-driven NSCLC and concluded the efficacy of altered subtypes.<h4>Methods</h4>A literature search was performed using PubMed, Web of Science, and Cochrane databases. The primary endpoints included the objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients with oncogene-driven NS"],"journal":["Therapeutic advances in medical oncology"],"pubmed_title":["Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis."],"pmcid":["PMC10901068"],"funding_grant_id":["82002456","YYZD2021008","BE2019719","YYQN2021085"],"pubmed_authors":["Zhan P","Liu X","Ye M","Lv J","Lu W","Chen J","Chen M","Wang D","Cai Z","Lv T","Zhu S","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.","description":"<h4>Background</h4>Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, only about 20% of NSCLC patients can benefit from this treatment. At present, whether patients with driving gene-positive NSCLC can benefit from immunotherapy is one of the hot issues. Therefore, we conducted a meta-analysis to evaluate the efficacy of immunotherapy in patients with oncogene-driven NSCLC and concluded the efficacy of altered subtypes.<h4>Methods</h4>A literature search was performed using PubMed, Web of Science, and Cochrane databases. The primary endpoints included the objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) in patients with oncogene-driven NS","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-22T06:39:19.743Z","creation":"2025-04-05T21:48:47.818Z"},"accession":"S-EPMC10901068","cross_references":{"pubmed":["38420602"],"doi":["10.1177/17588359231225036"]}}